Toxicity of chemo- versus endocrine therapy in combination with dual HER2-targeted therapy with trastuzumab and pertuzumab plus ribociclib in patients with HER2 positive and hormone-receptor positive metastatic breast cancer - results from an Interim Safety Analysis of DETECT V
ONCOLOGY RESEARCH AND TREATMENT. Bd. 45. H. SUPPL 3. 2022 S. 26-26
Erscheinungsjahr: 2022
Publikationstyp: Zeitschriftenaufsatz
| Geprüft | Bibliothek |
Autoren
Schochter, Fabienne (Autor)
Huober, Jens (Autor)
Fehm, Tanja (Autor)
Mueller, Volkmar (Autor)
Rack, Brigitte (Autor)
Just, Marianne (Autor)
Sagasser, Jacqueline (Autor)
Schmidt, Marcus (Autor)
Decker, Thomas (Autor)
Hartkopf, Andreas (Autor)
Schneeweiss, Andreas (Autor)
Friedl, Thomas W. P. (Autor)
Janni, Wolfgang (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
